Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 200Osteosarcoma 74Sarcoma, Ewing 50Rhabdomyosarcoma 48Melanoma 42Neuroblastoma 38Gastrointestinal Stromal Tumors 35Neoplasms 34Neoplasm Metastasis 32Bone Neoplasms 32Colorectal Neoplasms 31Glioblastoma 29Breast Neoplasms 25Ovarian Neoplasms 24Wilms Tumor 23Rhabdoid Tumor 23Gliosarcoma 23Glioma 23Liposarcoma 22Carcinoma, Non-Small-Cell Lung 22Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Neurofibrosarcoma 20Carcinoma, Renal Cell 20Pancreatic Neoplasms 19Medulloblastoma 19Hepatoblastoma 19Desmoid Tumors 18Thyroid Neoplasms 17Lymphoma 17

Interventions

ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1X-Rays 1Vemurafenib 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1LY3023414 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xanthogranuloma, Juvenile × Sarcoma × 90 days × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡